rs1800470
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
Consecutive patients (n = 660) with breast cancer from the Memorial Sloan-Kettering Cancer Center (New York, NY) and healthy females (n = 880) from New York City were genotyped for the hypomorphic TGFBR1*6A allele and for the TGFB1 T29C variant that results in increased TGF-beta circulating levels.
|
15833881 |
2005 |
rs1800470
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
We found no evidence for an association of the L10P SNP with breast cancer risk (per-allele odds ratio: 0.91; 95% confidence interval: 0.71-1.16).
|
23887657 |
2013 |
rs1800470
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
Four-locus (rs1800472-rs1800471-rs1800470-rs1800469) Haploview analysis identified haplotype <u>T</u>G<u>CT</u> to be negatively associated, and haplotypes CGT<u>T</u> and C<u>CC</u>C to be positively associated with BC.
|
31405342 |
2019 |
rs1800470
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
Conclusively, this meta-analysis strongly suggests that TGFB1 L10P polymorphism may play a low penetrance role in breast cancer susceptibility in Caucasian.
|
20349130 |
2010 |
rs1800470
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
Moreover, TGF-β1 29T>C genetic polymorphism is known to affect survival among breast cancer patients.
|
20506050 |
2010 |
rs1800470
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
We conclude that the TGFB1 L10P polymorphism is not associated with breast cancer risk.
|
14607332 |
2003 |
rs1800470
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
TGFB1 L10P polymorphism is associated with breast cancer susceptibility: evidence from a meta-analysis involving 47,817 subjects.
|
20143152 |
2010 |
rs1800470
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
The purposes of this study were to analyse the genotype of TGF-beta1 at T29C and TGF-beta1 phenotype in breast tumours, and to evaluate their associations with IGFs and clinical characteristics of breast cancer.
|
18827819 |
2008 |
rs1800470
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
Findings of the present study supports that the Pro10Leu, rs1982073, or rs1800470 SNP in <i>TGF-β1</i> is found to be expressed significantly more in GBM patients as it was found in breast cancer.
|
31160907 |
2019 |
rs1800470
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this study, we evaluated the association of the SNP rs1982073 (Leu10Pro) in transforming growth factor-beta 1 (TGFB1) gene and the SNP rs1219648 in fibroblast growth factor receptor 2 (FGFR2) gene with the risk and aggressiveness of breast cancer among women of Han nationality in North China.
|
20640597 |
2011 |
rs1800470
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
For five SNPs--CASP8 D302H, IGFBP3 -202 c>a, PGR V660L, SOD2 V16A, and TGFB1 L10P--the associations with breast cancer were of borderline statistical significance (P = .016, .060, .047, .056, and .0088 respectively).
|
17018785 |
2006 |
rs1800470
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
It can be concluded that TGF-β1 29T/C polymorphism does not play a role in breast cancer susceptibility in overall or ethnicity-specific manner.
|
25374198 |
2014 |
rs1800470
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
c.29C>T and c.74G>C polymorphisms in the TGF-β1 gene significantly affect breast cancer risk, which correlates with elevated TGF-β1 level in the patients.
|
24146803 |
2013 |
rs1800470
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
Conversely, low TGFβ1 production variants (C29T SNP and GCTG haplotype) were protective against HER2<sup>+</sup> tumors and correlated negatively with prognostic parameters in HER2<sup>+</sup> and TN BCs, while indicating higher proliferation rates in ER/PR<sup>+</sup>HER2<sup>-</sup> tumors.
|
29362917 |
2018 |
rs1800470
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
These results do not support the hypothesis that TGFB1 L10P genotypes modify the risk of breast cancer in BRCA1 or BRCA2 mutation carriers.
|
18523885 |
2009 |
rs1800470
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our study suggests there might be an association between the TGFβ1 29C>T polymorphism and CVD risk in long-term breast cancer survivors.
|
22100658 |
2012 |
rs1800470
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our data suggest that the TGF-beta1 Leu10Pro polymorphism might play a role in breast cancer risk.
|
17035001 |
2007 |
rs1800470
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
Transforming growth factor β1 (TGFB1) T29C and TGF β receptor type 1 (TGFBR1) 6A/9A polymorphisms have been implicated in the modulation of risk for breast cancer in Caucasian women.
|
21829601 |
2011 |
rs1800470
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our analysis suggested that 29T/C</span> has no association with a trend of breast cancer</span> risk when using both dominant [odds ratio (OR) = 1.01, 95% confidence intervals (CI) 0.96-1.07] and recessive models (OR = 0.98, 95% CI 0.89-1.08) to analyze the data.
|
20845106 |
2010 |
rs1800470
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
To evaluate the potential influences of TGF-beta1 T29C and TNF-beta A252G gene polymorphisms on breast cancer risk, a case-control study was conducted in Korea.
|
15803361 |
2005 |
rs1800470
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
A T29C transition polymorphism in the TGFB1 gene has been associated with higher circulating TGF-beta1 levels, and inconsistently with breast cancer risk in three recent studies.
|
15006917 |
2004 |
rs1800470
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
Overall, no significant associations between the TGFB1 T29C polymorphism and breast cancer risk were found for CC versus TT (OR = 1.00, 95% CI = 0.92-1.09), TC versus TT (OR = 0.98, 95% CI = 0.93-1.05), CC/TC versus TT (OR = 0.99, 95% CI = 0.93-1.05), and CC versus TC/TT (OR = 1.00, 95% CI = 0.93-1.08).
|
20157775 |
2010 |